EP Patent

EP1545516B1 — Topical formulation comprising at least 10% of metronidazole in white petrolatum and its use in the anal and rectal region

Assigned to SLA Pharma AG · Expires 2008-09-03 · 18y expired

What this patent protects

A topical composition comprising about 5 wt % to about 12.5 wt % of metronidazole or a pharmacologically acceptable salt thereof in a non-aqueous vehicle. The composition may be used in the treatment of skin damage due to inflammatory skin conditions; thermal, chemical or electri…

USPTO Abstract

A topical composition comprising about 5 wt % to about 12.5 wt % of metronidazole or a pharmacologically acceptable salt thereof in a non-aqueous vehicle. The composition may be used in the treatment of skin damage due to inflammatory skin conditions; thermal, chemical or electrical burns; infections or radiation treatment. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect, and thus, side effects observed from systemic administration are avoided.

Drugs covered by this patent

Patent Metadata

Patent number
EP1545516B1
Jurisdiction
EP
Classification
—
Expires
2008-09-03
Drug substance claim
No
Drug product claim
No
Assignee
SLA Pharma AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.